Aprea Therapeutics (APRE) Misses Q4 EPS by 32c

Aprea Therapeutics (NASDAQ: APRE) reported Q4 EPS of ($0.32). Revenue for the quarter came in at $3.34 million.

For earnings history and earnings-related data on Aprea Therapeutics (APRE) click here.

You May Also Be Interested In

• Musalem: strong growth and investment influencing bond market - CNBC
• Leggett & Platt shareholders approve merger with Somnigroup
• Deere shares climb as fiscal Q3 earnings and revenue top estimates